{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:30:21Z","timestamp":1784043021653,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the association between intravenous immunoglobulin (IVIG) treatment and pregnancy outcomes among women with recurrent pregnancy loss (RPL) in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study involving RPL pregnant women who delivered at the Lanzhou University Second Hospital between April 2023 and August 2024. Participants were categorized into a treatment group (received IVIG during pregnancy) and a control group (not received). The pregnancy outcomes were live birth rate (LBR), preterm birth, birth weight, and neonatal unit admission. RPL pregnant women exposed to IVIG were matched to unexposed in a 1:1 ratio with propensity score matching (PSM), using the nearest neighbor matching. Multivariable logistics regression was used to assess the association between IVIG use during pregnancy and pregnancy outcomes. We further conducted a stratified analysis based on the mean daily dose and the gestational age at the initiation of IVIG administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 504 RPL pregnant women were included, of whom 173 received IVIG during pregnancy and 331 did not. After PSM, 276 patients were analyzed with balanced baseline characteristics. The primary analysis showed that IVIG treatment during pregnancy was associated with a significantly higher LBR compared to controls (60.1% vs. 44.9%; adjusted OR [aOR]=1.960). This association remained significant after excluding cases with embryonic abnormal karyotypes (64.3% vs. 46.3%; aOR=2.187). Stratified analyses indicated that a mean daily IVIG dose &amp;lt;20 g was associated with improved LBR (aOR=2.484), and the benefit persisted after excluding abnormal karyotypes (aOR=3.000). Additionally, initiation of IVIG between 6\u201312 weeks\u2019 gestation yielded higher LBR (72.8% vs. 44.9%; aOR=3.253), especially among participants without abnormal karyotypes (76.6% vs. 46.3%; aOR=3.757). No significant associations were observed between IVIG use and preterm birth rate, birth weight, or neonatal unit admission rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IVIG use during pregnancy was associated with a significantly higher LBR among RPL women, particularly when initiated between 6\u201312 weeks of gestation and administered at a dose &amp;lt;20 g\/d; these associations remained robust after excluding cases with abnormal karyotypes. These findings suggest that IVIG may be an effective immunological intervention for improving pregnancy outcomes in selected RPL patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1689166","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:44:05Z","timestamp":1769582645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Early intravenous immunoglobulin use improves live birth outcomes in women with recurrent pregnancy loss: a propensity score\u2013matched cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenhu","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxiang","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoad002","article-title":"ESHRE guideline: recurrent pregnancy loss: an update in 2022","volume":"2023","author":"Bender Atik","year":"2023","journal-title":"Hum Reprod Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/biology14070877","article-title":"Immunological factors in recurrent pregnancy loss: mechanisms, controversies, and emerging therapies","volume":"14","author":"Moustakli","year":"2025","journal-title":"Biology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3390\/jcm12041250","article-title":"Successful pregnancy and delivery at term following intravenous immunoglobulin therapy with heparin for unexplained recurrent pregnancy loss suspected of immunological abnormalities: A case report and brief literature review","volume":"12","author":"Mitsui","year":"2023","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/ijms26020785","article-title":"A review of immunological evaluation of patients with recurrent spontaneous abortion (RSA)","volume":"26","author":"Andreescu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/antib12010020","article-title":"Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine","volume":"12","author":"Velikova","year":"2023","journal-title":"Antibodies (Basel Switzerland)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq179","article-title":"Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial","volume":"25","author":"Stephenson","year":"2010","journal-title":"Hum Reprod (Oxford England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13192","article-title":"Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomized, double-blind, placebo-controlled trial","volume":"122","author":"Christiansen","year":"2015","journal-title":"BJOG: an Int J Obstet Gynecol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/17.3.809","article-title":"A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage","volume":"17","author":"Christiansen","year":"2002","journal-title":"Hum Reprod (Oxford England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1569819","article-title":"Efficacy of therapeutic interventions for idiopathic recurrent pregnancy loss: a systematic review and network meta-analysis","volume":"12","author":"Lima","year":"2025","journal-title":"Front Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.jri.2025.104541","article-title":"Intravenous immunoglobulin versus placebo in recurrent pregnancy loss: A systematic review and meta-analysis of randomized trials","volume":"170","author":"Kofod","year":"2025","journal-title":"J Reprod Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e106024","DOI":"10.1136\/bmjopen-2025-106024","article-title":"Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"N\u00f8rgaard-Pedersen","year":"2025","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e13395","DOI":"10.1111\/aji.13395","article-title":"A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses","volume":"85","author":"Saab","year":"2021","journal-title":"Am J Reprod Immunol (New York NY: 1989)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.27821","article-title":"Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function","volume":"120","author":"Jafarzadeh","year":"2019","journal-title":"J Cell Biochem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13737","DOI":"10.1111\/aji.13737","article-title":"Intravenous immunoglobulin use in patients with unexplained recurrent pregnancy loss","volume":"90","author":"Banjar","year":"2023","journal-title":"Am J Reprod Immunol (New York NY: 1989)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104322","DOI":"10.1016\/j.jri.2024.104322","article-title":"Intravenous immunoglobulin improves live birth rates in patients with unexplained recurrent pregnancy loss","volume":"166","author":"Mu","year":"2024","journal-title":"J Reprod Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00973","article-title":"Propensity score methods in health technology assessment: principles, extended applications, and recent advances","volume":"10","author":"Ali","year":"2019","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp17X692153","article-title":"Comparison between treatment effects in a randomized controlled trial and an observational study using propensity scores in primary care","volume":"67","author":"Stuart","year":"2017","journal-title":"Br J Gen Pract: J R Coll Gen Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02025","article-title":"T helper (Th) cell profiles in pregnancy and recurrent pregnancy losses: th1\/th2\/th9\/th17\/th22\/tfh cells","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.607669","article-title":"How do uterine natural killer and innate lymphoid cells contribute to successful pregnancy","volume":"12","author":"Huhn","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6672865","DOI":"10.1155\/2020\/6672865","article-title":"Is there a role of intravenous immunoglobulin in immunologic recurrent pregnancy loss","volume":"2020","author":"Yang","year":"2020","journal-title":"J Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27627","article-title":"NK cell frequency and cytotoxicity in correlation to pregnancy outcome and response to IVIG therapy among women with recurrent pregnancy loss","volume":"234","author":"Ahmadi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jri.2015.01.008","article-title":"Medium-dose intravenous immunoglobulin therapy for women with six or more recurrent miscarriages","volume":"109","author":"Yamada","year":"2015","journal-title":"J Reprod Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.06.001","article-title":"Effect of Intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (RPL)","volume":"92","author":"Ahmadi","year":"2017","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0897.2003.01169.x","article-title":"Effect of intravenous immunoglobulin treatment on the Th1\/Th2 balance in women with recurrent spontaneous abortions","volume":"49","author":"Graphou","year":"2003","journal-title":"Am J Reprod Immunol (New York NY: 1989)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.3346\/jkms.2022.37.e200","article-title":"Outcomes of empirical treatment with intravenous immunoglobulin G combined with low-dose aspirin in women with unexplained recurrent pregnancy loss","volume":"37","author":"Kim","year":"2022","journal-title":"J Korean Med Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e13615","DOI":"10.1111\/aji.13615","article-title":"Efficacy of intravenous immunoglobulin in the treatment of recurrent spontaneous abortion: A systematic review and meta-analysis","volume":"88","author":"Shi","year":"2022","journal-title":"Am J Reprod Immunol (New York NY: 1989)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1381461","article-title":"Effect of IVIG therapy on pregnant women with unexplained recurrent spontaneous abortion: a systematic review and meta-analysis","volume":"15","author":"Ling","year":"2024","journal-title":"Front Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101527","DOI":"10.1016\/j.eclinm.2022.101527","article-title":"Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomized, placebo-controlled trial","volume":"50","author":"Yamada","year":"2022","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1689166\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:44:08Z","timestamp":1769582648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1689166\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1689166"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1689166","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"article-number":"1689166"}}